Thrivent Financial For Lutherans Halozyme Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

$28.6 Billion
Q1 2025

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$42.57 - $61.09 $8.25 Million - $11.8 Million	-193,810 Reduced 83.17%	39,206 $1.87 Million
Q3 2024 Nov 07, 2024	SELL	$51.3 - $64.42 $36.4 Million - $45.7 Million	-709,813 Reduced 75.29%	233,016 $13.3 Million
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $29.2 Million - $40.5 Million	-772,015 Reduced 45.02%	942,829 $49.4 Million
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $6.97 Million - $8.68 Million	-206,815 Reduced 10.76%	1,714,844 $69.8 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $3.08 Million - $3.9 Million	-92,574 Reduced 4.6%	1,921,659 $71 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $2.36 Million - $2.84 Million	-64,605 Reduced 3.11%	2,014,233 $76.9 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $30.3 Million - $38.8 Million	1,002,122 Added 93.07%	2,078,838 $75 Million
Q1 2023 May 17, 2023	BUY	$32.86 - $55.7 $5.16 Million - $8.75 Million	157,080 Added 17.08%	1,076,716 $41.1 Million
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $15.9 Million - $23.7 Million	-398,096 Reduced 30.21%	919,636 $52.3 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $320,800 - $431,120	-8,326 Reduced 0.63%	1,317,732 $52.1 Million
Q2 2022 Aug 16, 2022	SELL	$37.35 - $48.3 $5.26 Million - $6.81 Million	-140,910 Reduced 9.61%	1,326,058 $58.3 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $12.5 Million - $16 Million	390,135 Added 36.23%	1,466,968 $58.5 Million
Q4 2021 Feb 16, 2022	BUY	$31.82 - $40.75 $10.3 Million - $13.2 Million	323,585 Added 42.96%	1,076,833 $43.3 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $556,276 - $671,233	-14,460 Reduced 1.88%	753,248 $30.6 Million
Q2 2021 Aug 19, 2021	BUY	$38.84 - $51.31 $1.31 Million - $1.73 Million	33,732 Added 4.6%	767,708 $34.9 Million
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $20.3 Million - $26.4 Million	-512,639 Reduced 41.12%	733,976 $30.6 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $1.47 Million - $2.48 Million	56,814 Added 4.78%	1,246,615 $53.2 Million
Q3 2020 Nov 10, 2020	BUY	$25.74 - $29.63 $268,288 - $308,833	10,423 Added 0.88%	1,189,801 $31.3 Million
Q2 2020 Aug 12, 2020	BUY	$16.25 - $26.81 $84,012 - $138,607	5,170 Added 0.44%	1,179,378 $31.6 Million
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $44,924 - $70,554	-3,232 Reduced 0.27%	1,174,208 $21.1 Million
Q4 2019 Feb 13, 2020	SELL	$14.93 - $19.53 $40.1 Million - $52.5 Million	-2,688,279 Reduced 69.54%	1,177,440 $20.9 Million
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $1.22 Million - $1.42 Million	80,054 Added 2.11%	3,865,719 $60 Million
Q2 2019 Aug 13, 2019	BUY	$14.75 - $17.26 $1.71 Million - $2 Million	115,835 Added 3.16%	3,785,665 $65 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $1.5 Million - $1.89 Million	107,325 Added 3.01%	3,669,830 $59.1 Million
Q4 2018 Feb 15, 2019	BUY	$13.33 - $18.66 $5.69 Million - $7.96 Million	426,775 Added 13.61%	3,562,505 $52.1 Million
Q3 2018 Nov 15, 2018	BUY	$16.68 - $18.41 $13.7 Million - $15.1 Million	819,593 Added 35.39%	3,135,730 $57 Million
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $39.1 Million - $47 Million	2,316,137 New	2,316,137 $39.1 Million

Others Institutions Holding HALO

# of Institutions

594

Shares Held

124M

Call Options Held

320K

Put Options Held

113K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.88B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account